Abstract
B-cell lymphoma/leukaemia 11B (BCL11B) is an essential transcription factor for T-cell lineage commitment and maturation. We investigated BCL11B expression by immunohistochemistry in T-lymphoblastic leukaemia/lymphoma (T-ALL/LBL) (n = 115). The majority (83%) of early T-cell precursor T-ALL/LBL (ETP-ALL) cases showed negative BCL11B expression, while most (84%) of non-ETP-ALL/LBL were positive for BCL11B. A simplified three-marker [BCL11B, cluster of differentiation 5 (CD5), CD13] immunophenotypic score discriminated reliably between ETP-ALL and non-ETP-ALL/LBL. In ETP-ALL, patients with positive BCL11B expression had a better overall survival than those with negative BCL11B (P = 0·009). In summary, BCL11B is a valuable marker for T-ALL/LBL subtyping and serves as a potential prognostic marker in patients with ETP-ALL.
Original language | English (US) |
---|---|
Pages (from-to) | 1034-1038 |
Number of pages | 5 |
Journal | British Journal of Haematology |
Volume | 194 |
Issue number | 6 |
DOIs | |
State | Published - Sep 2021 |
Externally published | Yes |
Keywords
- BCL11B
- early T-cell precursor lymphoblastic leukaemia
- immunohistochemistry
- T-cell differentiation
- T-lymphoblastic leukaemia/lymphoma
ASJC Scopus subject areas
- Hematology